We previously demonstrated that celecoxib, a specific COX-2 inhibitor, significantly augmented the effectiveness of a DC-based breast cancer vaccine in reducing primary tumor burden, preventing metastasis, and increasing survival. Here, PTGS2 is linked to breast carcinoma.